[18F]Fluorodeoxyglucose-positron emission tomography screening for lung cancer

A systematic review and meta-analysis

Chun Ru Chien, Ji An Liang, Jin Hua Chen, Hsiao Nin Wang, Cheng Chieh Lin, Chih Yi Chen, Pin Hui Wang, Chia Hung Kao, Jun Jun Yeh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Rationale and objectives: Although low-dose computed tomography (CT) is a recommended modality for lung cancer screening in high-risk populations, the role of other modalities, such as [18F]fluorodeoxyglucose-positron emission tomography (PET), is unclear. We conducted a systematic review to describe the role of PET in lung cancer screening. Materials and methods: A systematic review was conducted by reviewing primary studies focusing on PET screening for lung cancer until July 2012. Two independent reviewers identified studies that were compatible for inclusion/exclusion criteria. The analysis was restricted to English and included studies published since 2000. A descriptive analysis was used to summarize the results, and the pooled diagnostic performance of selective PET screening was calculated by weighted average using individual sample sizes. Results: Among the identified studies (n = 3497), 12 studies were included for analysis. None of the studies evaluated the efficacy of primary PET screening specific to lung cancer. Eight studies focused on primary PET screening for all types of cancer; the detection rates of lung cancer were low. Four studies reported evidence of lung cancer screening programs with selective PET, in which the estimated pooled sensitivity and specificity was 83% and 91%, respectively. Conclusions: The role of primary PET screening for lung cancer remains unknown. However, PET has high sensitivity and specificity as a selective screening modality. Further studies must be conducted to evaluate the use of PET or PET/computed tomography screening for high-risk populations, preferably using randomized trials or prospective registration. Advances in knowledge: Our meta-analysis indicates that PET has high sensitivity and specificity as a selective screening modality.

Original languageEnglish
Pages (from-to)458-465
Number of pages8
JournalCancer Imaging
Volume13
Issue number4
DOIs
Publication statusPublished - Dec 11 2013

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Meta-Analysis
Lung Neoplasms
Early Detection of Cancer
Sensitivity and Specificity
Sample Size
Population
Tomography

Keywords

  • Cancer screening
  • Lung cancer
  • Positron emission tomography

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

[18F]Fluorodeoxyglucose-positron emission tomography screening for lung cancer : A systematic review and meta-analysis. / Chien, Chun Ru; Liang, Ji An; Chen, Jin Hua; Wang, Hsiao Nin; Lin, Cheng Chieh; Chen, Chih Yi; Wang, Pin Hui; Kao, Chia Hung; Yeh, Jun Jun.

In: Cancer Imaging, Vol. 13, No. 4, 11.12.2013, p. 458-465.

Research output: Contribution to journalArticle

Chien, Chun Ru ; Liang, Ji An ; Chen, Jin Hua ; Wang, Hsiao Nin ; Lin, Cheng Chieh ; Chen, Chih Yi ; Wang, Pin Hui ; Kao, Chia Hung ; Yeh, Jun Jun. / [18F]Fluorodeoxyglucose-positron emission tomography screening for lung cancer : A systematic review and meta-analysis. In: Cancer Imaging. 2013 ; Vol. 13, No. 4. pp. 458-465.
@article{901331e7284c4cb18c828c2ad0ac7e42,
title = "[18F]Fluorodeoxyglucose-positron emission tomography screening for lung cancer: A systematic review and meta-analysis",
abstract = "Rationale and objectives: Although low-dose computed tomography (CT) is a recommended modality for lung cancer screening in high-risk populations, the role of other modalities, such as [18F]fluorodeoxyglucose-positron emission tomography (PET), is unclear. We conducted a systematic review to describe the role of PET in lung cancer screening. Materials and methods: A systematic review was conducted by reviewing primary studies focusing on PET screening for lung cancer until July 2012. Two independent reviewers identified studies that were compatible for inclusion/exclusion criteria. The analysis was restricted to English and included studies published since 2000. A descriptive analysis was used to summarize the results, and the pooled diagnostic performance of selective PET screening was calculated by weighted average using individual sample sizes. Results: Among the identified studies (n = 3497), 12 studies were included for analysis. None of the studies evaluated the efficacy of primary PET screening specific to lung cancer. Eight studies focused on primary PET screening for all types of cancer; the detection rates of lung cancer were low. Four studies reported evidence of lung cancer screening programs with selective PET, in which the estimated pooled sensitivity and specificity was 83{\%} and 91{\%}, respectively. Conclusions: The role of primary PET screening for lung cancer remains unknown. However, PET has high sensitivity and specificity as a selective screening modality. Further studies must be conducted to evaluate the use of PET or PET/computed tomography screening for high-risk populations, preferably using randomized trials or prospective registration. Advances in knowledge: Our meta-analysis indicates that PET has high sensitivity and specificity as a selective screening modality.",
keywords = "Cancer screening, Lung cancer, Positron emission tomography",
author = "Chien, {Chun Ru} and Liang, {Ji An} and Chen, {Jin Hua} and Wang, {Hsiao Nin} and Lin, {Cheng Chieh} and Chen, {Chih Yi} and Wang, {Pin Hui} and Kao, {Chia Hung} and Yeh, {Jun Jun}",
year = "2013",
month = "12",
day = "11",
doi = "10.1102/1470-7330.2013.0038",
language = "English",
volume = "13",
pages = "458--465",
journal = "Cancer Imaging",
issn = "1740-5025",
publisher = "e-med",
number = "4",

}

TY - JOUR

T1 - [18F]Fluorodeoxyglucose-positron emission tomography screening for lung cancer

T2 - A systematic review and meta-analysis

AU - Chien, Chun Ru

AU - Liang, Ji An

AU - Chen, Jin Hua

AU - Wang, Hsiao Nin

AU - Lin, Cheng Chieh

AU - Chen, Chih Yi

AU - Wang, Pin Hui

AU - Kao, Chia Hung

AU - Yeh, Jun Jun

PY - 2013/12/11

Y1 - 2013/12/11

N2 - Rationale and objectives: Although low-dose computed tomography (CT) is a recommended modality for lung cancer screening in high-risk populations, the role of other modalities, such as [18F]fluorodeoxyglucose-positron emission tomography (PET), is unclear. We conducted a systematic review to describe the role of PET in lung cancer screening. Materials and methods: A systematic review was conducted by reviewing primary studies focusing on PET screening for lung cancer until July 2012. Two independent reviewers identified studies that were compatible for inclusion/exclusion criteria. The analysis was restricted to English and included studies published since 2000. A descriptive analysis was used to summarize the results, and the pooled diagnostic performance of selective PET screening was calculated by weighted average using individual sample sizes. Results: Among the identified studies (n = 3497), 12 studies were included for analysis. None of the studies evaluated the efficacy of primary PET screening specific to lung cancer. Eight studies focused on primary PET screening for all types of cancer; the detection rates of lung cancer were low. Four studies reported evidence of lung cancer screening programs with selective PET, in which the estimated pooled sensitivity and specificity was 83% and 91%, respectively. Conclusions: The role of primary PET screening for lung cancer remains unknown. However, PET has high sensitivity and specificity as a selective screening modality. Further studies must be conducted to evaluate the use of PET or PET/computed tomography screening for high-risk populations, preferably using randomized trials or prospective registration. Advances in knowledge: Our meta-analysis indicates that PET has high sensitivity and specificity as a selective screening modality.

AB - Rationale and objectives: Although low-dose computed tomography (CT) is a recommended modality for lung cancer screening in high-risk populations, the role of other modalities, such as [18F]fluorodeoxyglucose-positron emission tomography (PET), is unclear. We conducted a systematic review to describe the role of PET in lung cancer screening. Materials and methods: A systematic review was conducted by reviewing primary studies focusing on PET screening for lung cancer until July 2012. Two independent reviewers identified studies that were compatible for inclusion/exclusion criteria. The analysis was restricted to English and included studies published since 2000. A descriptive analysis was used to summarize the results, and the pooled diagnostic performance of selective PET screening was calculated by weighted average using individual sample sizes. Results: Among the identified studies (n = 3497), 12 studies were included for analysis. None of the studies evaluated the efficacy of primary PET screening specific to lung cancer. Eight studies focused on primary PET screening for all types of cancer; the detection rates of lung cancer were low. Four studies reported evidence of lung cancer screening programs with selective PET, in which the estimated pooled sensitivity and specificity was 83% and 91%, respectively. Conclusions: The role of primary PET screening for lung cancer remains unknown. However, PET has high sensitivity and specificity as a selective screening modality. Further studies must be conducted to evaluate the use of PET or PET/computed tomography screening for high-risk populations, preferably using randomized trials or prospective registration. Advances in knowledge: Our meta-analysis indicates that PET has high sensitivity and specificity as a selective screening modality.

KW - Cancer screening

KW - Lung cancer

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84890208495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890208495&partnerID=8YFLogxK

U2 - 10.1102/1470-7330.2013.0038

DO - 10.1102/1470-7330.2013.0038

M3 - Article

VL - 13

SP - 458

EP - 465

JO - Cancer Imaging

JF - Cancer Imaging

SN - 1740-5025

IS - 4

ER -